High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma

Haematologica. 2005 Nov;90(11):1580-2.

Abstract

We retrospectively investigated the outcome of 30 newly diagnosed patients with mantle cell lymphoma treated with high-dose therapy and autologous stem cell transplantation in first response. With a median follow-up of 55 months, the 5-year overall-survival is 62%, the 5-year progression-free-survival is 40% and no secondary malignancy has occurred.

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Lymphoma, Mantle-Cell / mortality
  • Lymphoma, Mantle-Cell / surgery*
  • Male
  • Middle Aged
  • Prednisone / administration & dosage
  • Retrospective Studies
  • Stem Cell Transplantation / methods*
  • Survival Analysis
  • Transplantation, Autologous
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol